- Home
- KWE vs CERO Comparison
KWE vs CERO Comparison
Compare KWE & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KWE
- CERO
- Stock Information
- Founded
- KWE 2017
- CERO 2017
- Country
- KWE Canada
- CERO United States
- Employees
- KWE N/A
- CERO N/A
- Industry
- KWE
- CERO
- Sector
- KWE
- CERO
- Exchange
- KWE Nasdaq
- CERO Nasdaq
- Market Cap
- KWE 3.2M
- CERO 3.1M
- IPO Year
- KWE N/A
- CERO N/A
- Fundamental
- Price
- KWE $0.26
- CERO $0.73
- Analyst Decision
- KWE
- CERO
- Analyst Count
- KWE 0
- CERO 0
- Target Price
- KWE N/A
- CERO N/A
- AVG Volume (30 Days)
- KWE 339.7K
- CERO 1.0M
- Earning Date
- KWE 05-15-2025
- CERO 05-16-2025
- Dividend Yield
- KWE N/A
- CERO N/A
- EPS Growth
- KWE N/A
- CERO N/A
- EPS
- KWE N/A
- CERO N/A
- Revenue
- KWE $1,572,738.00
- CERO N/A
- Revenue This Year
- KWE N/A
- CERO N/A
- Revenue Next Year
- KWE N/A
- CERO N/A
- P/E Ratio
- KWE N/A
- CERO N/A
- Revenue Growth
- KWE 116.30
- CERO N/A
- 52 Week Low
- KWE $0.25
- CERO $0.65
- 52 Week High
- KWE $11.60
- CERO $223.00
- Technical
- Relative Strength Index (RSI)
- KWE 29.90
- CERO 26.02
- Support Level
- KWE $0.30
- CERO $0.65
- Resistance Level
- KWE $0.33
- CERO $0.80
- Average True Range (ATR)
- KWE 0.02
- CERO 0.10
- MACD
- KWE -0.00
- CERO 0.04
- Stochastic Oscillator
- KWE 7.56
- CERO 20.79
About KWE KWESST Micro Systems Inc.
KWESST Micro Systems Inc develops and commercializes next-generation tactical systems. The company offers breakthrough technology in lethal and non-lethal systems with broad application, including law enforcement and personal defence, modernized digitization of tactical forces for shared situational awareness and targeting, and counter-measures against threats such as drones, lasers and electronic detection.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.